Literature DB >> 17582000

Epstein-Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras/PI3-K/Akt Pathway.

Makoto Fukuda1, Richard Longnecker.   

Abstract

Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A) is widely expressed in EBV-infected cells within the infected human host and EBV-associated malignancies, suggesting that LMP2A is important for EBV latency, persistence, and EBV-associated tumorigenesis. Previously, we demonstrated that LMP2A provides an antiapoptotic signal through the activation of phosphatidylinositol 3-kinase (PI3-K)/Akt pathway in vitro. However, the exact function of LMP2A in tumor progression is not well understood. In this study, we found that LMP2A did not induce anchorage-independent cell growth in a human keratinocyte cell line, HaCaT, but did in a human gastric carcinoma cell line, HSC-39. In addition, LMP2A activated the PI3-K/Akt pathway in both HaCaT and HSC-39 cells; however, LMP2A did not activate Ras in HaCaT cells but did in HSC-39 cells. Furthermore, the Ras inhibitors manumycin A and a dominant-negative form of Ras (RasN17) and the PI3-K inhibitor LY294002 blocked LMP2A-mediated Akt phosphorylation and anchorage-independent cell growth in HSC-39 cells. These results suggest that constitutive activation of the Ras/PI3-K/Akt pathway by LMP2A is a key factor for LMP2A-mediated transformation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17582000      PMCID: PMC1951437          DOI: 10.1128/JVI.00537-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway.

Authors:  Toni Portis; Richard Longnecker
Journal:  Oncogene       Date:  2004-11-11       Impact factor: 9.867

Review 2.  Persistence of the Epstein-Barr virus and the origins of associated lymphomas.

Authors:  David A Thorley-Lawson; Andrew Gross
Journal:  N Engl J Med       Date:  2004-03-25       Impact factor: 91.245

3.  Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals.

Authors:  R G Caldwell; J B Wilson; S J Anderson; R Longnecker
Journal:  Immunity       Date:  1998-09       Impact factor: 31.745

4.  Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium.

Authors:  V H Freedman; S I Shin
Journal:  Cell       Date:  1974-12       Impact factor: 41.582

5.  Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency.

Authors:  S Fruehling; R Swart; K M Dolwick; E Kremmer; R Longnecker
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

6.  Epithelial cell adhesion to extracellular matrix proteins induces tyrosine phosphorylation of the Epstein-Barr virus latent membrane protein 2: a role for C-terminal Src kinase.

Authors:  F Scholle; R Longnecker; N Raab-Traub
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

7.  Roles of the ITAM and PY motifs of Epstein-Barr virus latent membrane protein 2A in the inhibition of epithelial cell differentiation and activation of {beta}-catenin signaling.

Authors:  Jennifer A Morrison; Nancy Raab-Traub
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

8.  Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A.

Authors:  Cary A Moody; Rona S Scott; Nazanin Amirghahari; Cherie-Ann Nathan; Lawrence S Young; Chris W Dawson; John W Sixbey
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

9.  Epstein-Barr virus lacking latent membrane protein 2 immortalizes B cells with efficiency indistinguishable from that of wild-type virus.

Authors:  Peter Speck; Kimberly A Kline; Paul Cheresh; Richard Longnecker
Journal:  J Gen Virol       Date:  1999-08       Impact factor: 3.891

10.  Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma.

Authors:  Jennifer A Morrison; Margaret L Gulley; Rajadurai Pathmanathan; Nancy Raab-Traub
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

View more
  46 in total

Review 1.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

2.  Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma.

Authors:  Osman Cen; Richard Longnecker
Journal:  Mol Cancer Ther       Date:  2011-01-31       Impact factor: 6.261

3.  An auto-regulatory loop for EBV LMP2A involves activation of Notch.

Authors:  Leah J Anderson; Richard Longnecker
Journal:  Virology       Date:  2007-11-05       Impact factor: 3.616

Review 4.  Microbiome and malignancy.

Authors:  Claudia S Plottel; Martin J Blaser
Journal:  Cell Host Microbe       Date:  2011-10-20       Impact factor: 21.023

Review 5.  T cell metabolism in chronic viral infection.

Authors:  L J Pallett; N Schmidt; A Schurich
Journal:  Clin Exp Immunol       Date:  2019-05-20       Impact factor: 4.330

Review 6.  The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  Chi Man Tsang; Sai Wah Tsao
Journal:  Virol Sin       Date:  2015-04-21       Impact factor: 4.327

7.  Role of the immunoreceptor tyrosine-based activation motif of latent membrane protein 2A (LMP2A) in Epstein-Barr virus LMP2A-induced cell transformation.

Authors:  Makoto Fukuda; Yasushi Kawaguchi
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

8.  Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma.

Authors:  Qing-Li Kong; Li-Juan Hu; Jing-Yan Cao; Yi-Jun Huang; Li-Hua Xu; Yi Liang; Dan Xiong; Su Guan; Bao-Hong Guo; Hai-Qiang Mai; Qiu-Yan Chen; Xing Zhang; Man-Zhi Li; Jian-Yong Shao; Chao-Nan Qian; Yun-Fei Xia; Li-Bing Song; Yi-Xin Zeng; Mu-Sheng Zeng
Journal:  PLoS Pathog       Date:  2010-06-03       Impact factor: 6.823

9.  Characterization of Epstein Barr virus latency pattern in Argentine breast carcinoma.

Authors:  Mario A Lorenzetti; Elena De Matteo; Hugo Gass; Paula Martinez Vazquez; Julia Lara; Pedro Gonzalez; María Victoria Preciado; Paola A Chabay
Journal:  PLoS One       Date:  2010-10-22       Impact factor: 3.240

10.  EBV LMP2A affects LMP1-mediated NF-kappaB signaling and survival of lymphoma cells by regulating TRAF2 expression.

Authors:  Ilaria Guasparri; Darya Bubman; Ethel Cesarman
Journal:  Blood       Date:  2008-01-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.